End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4272 USD | -3.87% | +1.23% | -12.30% |
30/04 | Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product | CI |
30/04 | Akili, Inc. to Reduce Workforce | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-12.30% | 33.58M | |
+11.29% | 226B | |
+8.76% | 188B | |
+12.90% | 137B | |
+25.95% | 108B | |
+0.34% | 63.19B | |
+11.08% | 52.26B | |
+5.62% | 51B | |
+6.28% | 43.89B | |
+4.80% | 38.07B |
- Stock Market
- Equities
- AKLI Stock
- News Akili, Inc.
- Morgan Stanley Adjusts Price Target on Akili to $3 From $2, Maintains Equal-Weight Rating